chondrosarcoma (Cancer)
Information
- Disease name
- chondrosarcoma
- Disease ID
- DOID:3371
- Description
- "A bone sarcoma that has_material_basis_in cells derived from transformed cells that produce cartilage." [url:http\://en.wikipedia.org/wiki/Chondrosarcoma]
Disease area statistics
Chromosome band
Annotation
Genes | Mutation | Description | Source | Links |
---|
NCT ID | Status | Phase | Summary | Start date | Completion date |
---|---|---|---|---|---|
NCT04521686 | Active, not recruiting | Phase 1 | Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations | October 16, 2020 | May 2025 |
NCT00496522 | Active, not recruiting | Phase 2 | Proton Beam Therapy for Chondrosarcoma | April 28, 2006 | August 19, 2024 |
NCT03173976 | Active, not recruiting | Phase 1 | Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial | July 18, 2017 | July 1, 2024 |
NCT04091295 | Available | BLESSED: Expanded Access for DeltaRex-G for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast | |||
NCT01154452 | Completed | Phase 1/Phase 2 | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma | June 2010 | February 2015 |
NCT01330966 | Completed | Phase 2 | Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma | April 2011 | February 2018 |
NCT02996747 | Completed | Low Grade Chondrosarcoma Versus Enchondroma | August 2016 | December 2016 | |
NCT01553539 | Completed | Phase 2 | Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery | October 2009 | January 2013 |
NCT01560260 | Completed | Phase 2 | Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors | March 2012 | October 2015 |
NCT01609179 | Completed | N/A | IPI-926 Extension Protocol for Continuation of Treatment With IPI-926 | March 2012 | November 2012 |
NCT02073994 | Completed | Phase 1 | Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation | March 1, 2014 | January 4, 2024 |
NCT02273739 | Completed | Phase 1/Phase 2 | Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation | December 8, 2014 | June 3, 2016 |
NCT02496741 | Completed | Phase 1/Phase 2 | Metformin And Chloroquine in IDH1/2-mutated Solid Tumors | November 2015 | November 18, 2019 |
NCT01336803 | Completed | Phase 2 | Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI | August 2011 | October 2023 |
NCT00004241 | Completed | Phase 1 | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma | October 1999 | |
NCT00464620 | Completed | Phase 2 | Trial of Dasatinib in Advanced Sarcomas | May 2007 | May 2017 |
NCT00592748 | Completed | Phase 1/Phase 2 | Charged Particle RT for Chordomas and Chondrosarcomas of the Base of Skull or Cervical Spine | June 1999 | May 2015 |
NCT03874455 | No longer available | Tazemetostat Expanded Access Program for Adults With Solid Tumors | |||
NCT06029478 | Not yet recruiting | Understanding Engagement Trends in Chondrosarcoma Clinical Trials | October 2024 | October 2026 | |
NCT06387485 | Recruiting | N/A | A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning | March 1, 2024 | April 1, 2025 |
NCT05033288 | Recruiting | Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone | January 20, 2022 | August 30, 2028 | |
NCT05039801 | Recruiting | Phase 1 | IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors | September 9, 2021 | May 29, 2026 |
NCT05193188 | Recruiting | Phase 2 | A Study of Anlotinib Combined With or Without PD-1 Antibody on Unresectable High-grade Chondrosarcoma | February 6, 2023 | March 31, 2026 |
NCT05779670 | Recruiting | Adherence to a Personalized Home Exercise Program in Patients With Bone Tumor Undergoing Lower Extremity Salvage Surgery | January 1, 2023 | December 31, 2025 | |
NCT05861245 | Recruiting | N/A | Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base | May 24, 2023 | May 24, 2033 |
NCT06029218 | Recruiting | N/A | Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy | September 13, 2023 | October 1, 2031 |
NCT03442465 | Recruiting | Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas | February 14, 2018 | February 14, 2025 | |
NCT03715933 | Recruiting | Phase 1 | Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | October 10, 2018 | July 2026 |
NCT04028479 | Recruiting | The Registry of Oncology Outcomes Associated With Testing and Treatment | May 5, 2021 | October 1, 2031 | |
NCT04040205 | Recruiting | Phase 2 | Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration | October 7, 2019 | June 1, 2027 |
NCT04055220 | Recruiting | N/A | Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas | March 3, 2020 | October 1, 2026 |
NCT04087902 | Recruiting | Long-Term Longitudinal QoL in Patients Undergoing EEA | July 16, 2019 | December 31, 2025 | |
NCT04278781 | Recruiting | Phase 2 | AG-120 in People With IDH1 Mutant Chondrosarcoma | March 4, 2020 | March 2026 |
NCT04553692 | Recruiting | Phase 1 | Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers | September 23, 2020 | August 2027 |
NCT04673942 | Recruiting | Phase 2 | A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors | March 29, 2021 | March 1, 2027 |
NCT04832620 | Recruiting | Image Assisted Optimization of Proton Radiation Therapy in Chordomas and Chondrosarcomas | February 2, 2021 | December 2027 | |
NCT02008019 | Suspended | Phase 2 | A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas | August 14, 2014 | August 2019 |
NCT00003292 | Terminated | Phase 2 | S9624 Ifosfamide in Treating Patients With Meningeal Tumors | July 1998 | January 2004 |
NCT00543712 | Terminated | Phase 2 | A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g) | May 31, 2007 | May 5, 2008 |
NCT02982486 | Unknown status | Phase 2 | A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma | December 2017 | December 2020 |
NCT01182753 | Unknown status | Phase 3 | Trial of Proton Versus Carbon Ion Radiation Therapy in Patients With Low and Inter-mediate Grade Chondrosarcoma of the Skull Base | August 2010 | August 2022 |
NCT02587169 | Unknown status | Phase 1/Phase 2 | Trial of Nilotinib and Adriamycin as Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum | January 2012 | December 2015 |
- Disase is a (Disease Ontology)
- DOID:0080639
- Cross Reference ID (Disease Ontology)
- GARD:6004
- Cross Reference ID (Disease Ontology)
- GARD:6055
- Cross Reference ID (Disease Ontology)
- ICDO:9220/3
- Cross Reference ID (Disease Ontology)
- MESH:D002813
- Cross Reference ID (Disease Ontology)
- MIM:215300
- Cross Reference ID (Disease Ontology)
- NCI:C2946
- Cross Reference ID (Disease Ontology)
- NCI:C7155
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:443520009
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:735679005
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0008479
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C1335473
- Exact Synonym (Disease Ontology)
- Cartilaginous cancer
- Exact Synonym (Disease Ontology)
- chondrosarcoma of bone
- Exact Synonym (Disease Ontology)
- primary chondrosarcoma of the bone
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0006765
- OrphaNumber from OrphaNet (Orphanet)
- 55880
- MeSH unique ID (MeSH (Medical Subject Headings))
- D002813